ValuEngine lowered shares of Vericel (NASDAQ:VCEL) from a hold rating to a sell rating in a research note published on Friday morning.
Several other analysts have also recently issued reports on the company. BTIG Research reiterated a buy rating and issued a $6.00 price objective on shares of Vericel in a research note on Thursday, September 7th. Piper Jaffray Companies reiterated a buy rating and issued a $7.00 price objective on shares of Vericel in a research note on Thursday, August 10th.
Shares of Vericel (NASDAQ:VCEL) opened at $4.85 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.22 and a current ratio of 2.50. Vericel has a 52 week low of $2.25 and a 52 week high of $6.30.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The business had revenue of $14.26 million for the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. equities research analysts anticipate that Vericel will post -0.6 EPS for the current year.
A number of institutional investors have recently bought and sold shares of the business. Archon Capital Management LLC raised its stake in Vericel by 95.7% in the third quarter. Archon Capital Management LLC now owns 2,617,004 shares of the biotechnology company’s stock valued at $15,702,000 after buying an additional 1,279,925 shares in the last quarter. Vanguard Group Inc. raised its stake in Vericel by 7.9% in the second quarter. Vanguard Group Inc. now owns 1,212,799 shares of the biotechnology company’s stock valued at $4,002,000 after buying an additional 88,645 shares in the last quarter. First Washington CORP acquired a new stake in Vericel in the second quarter valued at $2,230,000. Perkins Capital Management Inc. raised its stake in Vericel by 118.4% in the third quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after buying an additional 305,000 shares in the last quarter. Finally, EAM Investors LLC acquired a new stake in Vericel in the third quarter valued at $943,000. Institutional investors own 33.17% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Vericel (VCEL) Stock Rating Lowered by ValuEngine” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/vericel-vcel-stock-rating-lowered-by-valuengine.html.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.